Purpose: To investigate the association between the GABAergic drugs, benzodiazepines or zopiclone, and the occurrence of asthma exacerbations and subsequent mortality in a cohort of asthma patients.
INTRODUCTION
Asthma affects 235 million people globally 1 with estimated mortality of 1.1 and 1.6 per 100, risk factors, including medications that predispose to exacerbation of asthma and subsequent mortality.
Benzodiazepines are widely prescribed especially for the treatment of anxiety and insomnia, 4 through modulation of inhibitory Ɣ-amino butyric acid Type A (GABA A ) receptors in the brain. 5 Occasionally they may also be used in treatment of severe anxiety that presents during asthma attacks. 6 However they are not innocuous; accumulating evidence suggest they may cause harm 7, 8 , including increased mortality in the general population 9 and risk of cancer. 10 Benzodiazepines may also increase the risk from infection. [11] [12] [13] Obiora et al found that benzodiazepine exposure in the community was associated with an increased risk of pneumonia and subsequent all-cause mortality following pneumonia.
14 Meta-analysis of data from randomised controlled trials for non-benzodiazepine GABAergic hypnotics (zopiclone, ramelteon, zaleplon and zolpidem) also identified an increased risk of infection (risk ratio;
1.44, 95% confidence interval 1.25-1.64, p < 0.001). 15 These data support evidence from critical care where benzodiazepine sedation is associated with increase in mortality in septic patients relative to non-GABAergic sedation. 16 However, the data are somewhat inconsistent overall, with two studies 17, 18 suggesting a protective effect on pneumonia and some finding no statistical association. [19] [20] [21] With regards to all-cause mortality, a systematic review conducted in 2009 found mixed and inconclusive results. 22 Thus, further data are urgently required.
In asthma, increased expression of epithelial GABA A receptors leads to the overproduction of mucus. 23 Furthermore, allergen-induced asthma in mice increases the expression of benzodiazepine-sensitive GABA A receptors on alveolar macrophages. 13 Augmented
GABAergic signalling, such as through benzodiazepine treatment, impairs immune responses through intracellular acidosis of monocytes and macrophages, leading to increased mortality in animal models of infection 13, 24 supporting the observations in humans. 9, 14 Given the intrinsic role of the pulmonary GABAergic system in the pathogenesis of asthma and accumulating data on potential harms of benzodiazepines especially from infections, we have evaluated GABAergic drugs in asthmatic patients in relation to the occurrence of asthma exacerbations, and mortality following asthma exacerbation. 
METHODS

Data source
Outcome definition
The primary outcome for the nested case-control analysis was physician diagnosed asthma exacerbation (cases), identified using Read codes. We used hospital data to identify missing patients using the ICD 10 code for status asthmaticus (J46)/or a record of hospitalisation occurring within 14 days of a primary care diagnosis of asthma exacerbation. The date of the first recorded diagnosis of asthma exacerbation during the study period was designated the index date. All asthma patients, in the study population, who had not experienced an exacerbation during the study period, were identified as potential controls. These were individually matched to cases by age at index date (±3 years), sex and general practice (matching on general practice i.e. primary care clinic, was performed to account for differences in prescribing policies and patient management followed in various primary care clinical settings). A maximum of six controls were matched to each case to give sufficient sample size for stratified analyses. The sample size was calculated using the Dupont Power and Sample size program (Appendix 2). 26 The secondary outcome of interest was all-cause mortality (over a median follow-up time of 1.97 years) following a diagnosis of asthma exacerbation during the study period, investigated using survival analysis, including only those patients diagnosed with an asthma exacerbation (Appendix 1).
Exposure definition
Data were extracted for all recorded prescriptions of benzodiazepines and zopiclone. The most recent prescription prior to the asthma exacerbation diagnosis date (or the index date of the matched case for controls) was retained. Benzodiazepines were considered both as a class and as individual drugs. The three most frequently used individual benzodiazepines in the study population, namely, diazepam, temazepam and lorazepam were also identified for a priori stratified analyses, representing long-acting, intermediate and short-acting agents respectively. Exposure was considered current when the most recent prescription was within the 30 days prior to the index date. The most commonly prescribed oral benzodiazepines in the UK typically have a 20-28 tablet pack-size. 4 We used this to reason that long-term regular users of benzodiazepines would have repeat monthly prescriptions from their general practitioner. Presence of a repeat prescription defined long term drug use whereas the absence of it was considered short term use. Prescriptions in the period 31 to 90 days and >90 days before index date were classified as recent and past exposures respectively. No evidence of prescribing at any point in the patient's past primary care records defined 'never' users.
Potential confounders
A validated weighted, comorbidity index (Charlson's comorbidity index) was adopted as a measure of comorbidity burden. 27 In addition, we adjusted for depression, sleeping problems, psychosis, stress and anxiety, identified as important confounders in previous related studies 
Statistical analyses
Conditional logistic regression was used to investigate the association between drug exposure and asthma exacerbation. Cox regression modelling was used to assess the association between drug exposure and mortality following asthma exacerbation after checking that proportional hazards assumptions were met. Missing data were included in the analysis as dummy variables.
We constructed two multivariable models for each exposure variable: Model 1 included all covariates that were significantly associated with both asthma exacerbation and the exposure variable (p<0.05) and Model 2 included all potential confounders as listed in the previous section. We tested for interaction with comorbidities and where a statistically significant interaction was found the multivariable analysis was repeated, stratified by the interaction variable categories.
To quantify the proportion by which the incidence of asthma exacerbation among asthma patients would reduce if exposure to benzodiazepines was eliminated, 30 the adjusted attributable fraction (AF) among the exposed and the adjusted population attributable fraction (PAF) were determined using the user-generated package 'punaf' in Stata. 31, 32 We also calculated the unadjusted number needed to harm (the inverse of the absolute risk increase). 30 All statistical analyses were conducted in Stata version 12.
RESULTS
Characteristics of study participants
A total of 131,642 patients were included in the main analysis after excluding patients with anomalies in key dates e.g. registration and death dates (Appendix 1). Of these, 60,542(57.25%) were females, 32,311(30.56%) were aged below 18 years and 25,895(19.67%) had an asthma exacerbation of which nearly 8% (2,063) were severe.
Benzodiazepine exposure was noted in 20,725 patients, comprising 15.74% of the study population overall. Patients with asthma exacerbation were more likely to be from more deprived settings, have a diagnosis of depression, be current smokers, overweight or obese and have had a prescription of corticosteroids, opioids and beta-2 agonists (Table 1) . significance. Duration of benzodiazepine use did not alter the observed association with asthma exacerbation with both long-and short-term users at risk (Table 2) . Statistically significant interactions were found with Charlson's comorbidity index score. Table 3 shows the stratified analysis results. The association between anytime benzodiazepine use and asthma exacerbation was stronger among asthma patients without comorbidities.
Using unadjusted risks, we estimated that over a one year follow-up period, the number needed to harm was 22 (95% CI 12-109), indicating that for every 22 asthma patients prescribed benzodiazepines annually, one additional asthma exacerbation could be expected.
Moreover, in asthma patients prescribed benzodiazepines (20, Table 4 presents HRs for the association between benzodiazepines or zopiclone exposures and all-cause mortality subsequent to asthma exacerbation over the study period (median follow-up 1.97 years). Benzodiazepine use was found to be significantly associated with increased mortality following asthma exacerbation (adj HR 1.32; 95% CI 1.08-1.61; p=0.006) with current and recent prescriptions associated with the greatest effect. Individually, only diazepam was significantly associated with increased mortality over the study period (adj HR 1.27; 95% CI 1.01-1.59; P=0.037). However, the sample sizes were insufficient to fully investigate the individual effects of other benzodiazepines on mortality. The unadjusted number needed to harm (NNH) was estimated as 17(95% CI 9 -133); thus for every 17 asthma patients taking benzodiazepines, one additional death could be expected within a median follow-up time of 2 years. The association between current zopiclone use and all- 
Benzodiazepines and mortality following asthma exacerbation
DISCUSSION
Summary of main findings
The findings of this study suggest that use of benzodiazepines and zopiclone is associated with increased occurrence of asthma exacerbation and 2-year mortality after exacerbation; a heightened likelihood of exacerbation associated with current use increases biological plausibility. The high prevalence of asthma as a disease and, of benzodiazepines exposure (15.7%) in this representative cohort, suggests our findings have public health significance.
Strengths and limitations
To our knowledge, this is the first epidemiological study to examine benzodiazepine use and the occurrence of asthma exacerbation and subsequent mortality. Use of the CPRD database has enhanced the generalisability of these findings and also allowed adequately powered analyses. Data on drug exposures are collected prospectively, prior to asthma exacerbation, thus eliminating any recall bias. Moreover, reporting bias is virtually eliminated as data are routinely collected, prospectively by general practitioners during patient consultation for patient care and medico-legal record-keeping. Using cohort data eliminates any temporal biases relating to timing of exposure. A conditional logistic regression was performed with cases and controls individually matched on age, sex, and general practice and further adjustment for a wide range of potential confounders including Charlson's comorbidity index score 27 and other specific diseases identified as confounders of the relationship between benzodiazepines and disease outcomes (sleeping problems, anxiety, stress, psychosis and depression). 9, 14 In addition, the effect of other drugs that could be concurrently prescribed with benzodiazepines (e.g. opioids) and other factors that may trigger an asthma exacerbation The use of prescription data does not allow any assessment of compliance with treatment.
Whilst this could lead to misclassification of exposure, the effects are likely to be nondifferential and would therefore bias results towards unity. Nevertheless, the observed associations still remained when we assessed chronic benzodiazepine use as indicated by repeat prescriptions (Table 2 ).
Our calculations suggest that benzodiazepines may account for nearly 3.4% of exacerbations in asthma patients and that one additional asthma exacerbation would be triggered within a year of using benzodiazepines for every 22 asthma patients. In addition, our findings suggest that for every 17 asthma patients taking benzodiazepines, one additional death could be expected within a median follow-up time of 2 years. However, these results should be interpreted with caution as the NNH estimates are based on unadjusted risks; and while the PAF has been calculated using adjusted risk estimates, both measures assume a causal relationship that an observational study such as this cannot establish. Moreover, our study did not assess drug dosages. Future studies should look at drug dosages and frequency in greater detail.
Comparison with existing literature
It is not possible to make a direct comparison of the results from our study with earlier findings as ours is the first study we are aware of that directly assesses benzodiazepines effect in asthma patients. Recently a similar observation has been made for patients with chronic obstructive pulmonary disease where benzodiazepines increased outpatient exacerbations and visits to the emergency room. 8 Obiora et al also found that benzodiazepines were associated with an increased risk of pneumonia and pneumonia-related mortality in a non-selected population.
14 Results for both benzodiazepines as a class and individual benzodiazepines are in line with those from the current study. In both studies, the highest risks were observed in relation to current use of benzodiazepines, particularly diazepam. The diazepam finding may be attributable to its prolonged half-life and active metabolites. 36 However we suspect that the non-significant association observed for other individual benzodiazepines with mortality could be due to relatively low usage in the population studied and that this is in fact a drug class effect.
It is also interesting to note that patients with a lower comorbidity burden were at increased risk of worse outcome from benzodiazepines similar to previous observations with pneumonia. 14, 37 We surmise that the presence of comorbidity reduces the proportion of risk attributable to benzodiazepine exposure in the individual patient.
Our observation that benzodiazepine, and zopiclone exposure, are associated with an increased odds of asthma exacerbation is biologically plausible given the role of GABA A receptor signalling in the pathogenesis of asthma 23 and immunity in the lung. 13 While epidemiological studies cannot prove a causal relationship between benzodiazepines and asthma exacerbations, a large well-conducted epidemiological study can detect adverse drug effect signals that may be missed in the average randomised controlled drug trial. 38 Ideally, a large RCT should be conducted to investigate this association (for the outcome of 'exacerbations') ethical considerations permitting; alternatively, additional evidence from large prospective cohort studies, using standardised data collection protocols and selfcontrolled case series that would account for fixed confounding via intra-person comparisons, 39 could strengthen the existing evidence.
CONCLUSION
Benzodiazepines are prescribed in up to one-sixth of patients with asthma. This study shows that these drugs along with zopiclone may increase the risk of asthma exacerbation; the risk of mortality after exacerbation may also be increased. Caution should be exercised when prescribing benzodiazepines in patients with asthma.
Key points
• A high prevalence of benzodiazepines use (15.7%) was found in the asthma cohort studied.
• Having been prescribed a benzodiazepines within 30 days prior, was associated with an approximately 50% increased likelihood of asthma exacerbation.
• The non-benzodiazepine hypnotic, zopiclone, which also works via activation of GABA A receptors, was associated with a similar increase in the likelihood of asthma exacerbation.
• Both benzodiazepines and zopiclone were also found to be associated with increased mortality in the 2 years after an asthma exacerbation. 
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